These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Applicability of phase I trial results in the design of phase II and III biological response modifier trials. Pinsky CM Cancer Treat Rep; 1985 Oct; 69(10):1171-3. PubMed ID: 4042095 [No Abstract] [Full Text] [Related]
3. Biologicals and biological response modifiers: fourth modality of cancer treatment. Oldham RK Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081 [TBL] [Abstract][Full Text] [Related]
4. Assessment of biological responses: what to measure and when. Maluish AE; Herberman RB Cancer Treat Rep; 1985 Oct; 69(10):1165-9. PubMed ID: 3899356 [TBL] [Abstract][Full Text] [Related]
5. Biological Response Modifiers Programme and cancer chemotherapy. Oldham RK Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193 [TBL] [Abstract][Full Text] [Related]
7. The role of the individual and the community in the research, development, and use of biologicals. Cockburn WC WHO Chron; 1978 Jul; 32(7):283-5. PubMed ID: 695544 [No Abstract] [Full Text] [Related]
8. Are there special considerations relevant to trials of biologic agents? Strand V J Rheumatol Suppl; 1994 Sep; 41():41-5; discussion 45-9. PubMed ID: 7799384 [TBL] [Abstract][Full Text] [Related]
9. Issues related to clinical trials of oral and biologic disease-modifying agents for Sjögren's syndrome. Carsons SE Rheum Dis Clin North Am; 2008 Nov; 34(4):1011-23, x. PubMed ID: 18984419 [TBL] [Abstract][Full Text] [Related]
11. Commentary: enlisting community involvement for biologicals research. Kostrzewski J Bull World Health Organ; 1977; 55 Suppl 2(Suppl 2):127-30. PubMed ID: 343941 [No Abstract] [Full Text] [Related]
12. [Use of a biological preparation in the treatment of cervicobrachialgia and lumbosciatalgia]. Scapinelli R Clin Ortop; 1973; 24(3):203-9. PubMed ID: 4619064 [No Abstract] [Full Text] [Related]
15. The demand for human trials in biological research. Robbins FC Bull World Health Organ; 1977; 55 Suppl 2(Suppl 2):73-83. PubMed ID: 305319 [No Abstract] [Full Text] [Related]
16. Evaluation of biological response modifiers in vitro. Salmon SE J Biol Response Mod; 1983; 2(3):207-9. PubMed ID: 6196452 [No Abstract] [Full Text] [Related]
17. [Natural products in clinical trials: antiparasitic, antiviral and neurological drugs]. Zheng D; Han L; Huang XS; Yu SS; Liang XT Yao Xue Xue Bao; 2007 Jun; 42(6):576-82. PubMed ID: 17702391 [TBL] [Abstract][Full Text] [Related]
18. [Rheumatology-part 2. Research news concerning pathogenesis, epidemiology, diagnosis, and therapy of connective tissue disease]. Ahmadi-Simab K; Hellmich B; Lamprecht P; Gross WL Med Klin (Munich); 2006 Feb; 101(2):127-37. PubMed ID: 16501910 [TBL] [Abstract][Full Text] [Related]
19. [Possibilities and therapeutic limits of a biological preparation in arthro-neuralgias based on arthrosis]. Monteleone M Clin Ortop; 1973; 24(3):194-201. PubMed ID: 4619063 [No Abstract] [Full Text] [Related]
20. Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. Nixon RM; Bansback N; Stevens JW; Brennan A; Madan J Pharm Stat; 2009; 8(2):150-62. PubMed ID: 18942777 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]